12
Participants
Start Date
April 24, 2020
Primary Completion Date
December 1, 2023
Study Completion Date
October 7, 2024
Panitumumab
Given IV
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Regorafenib
Given PO
Trifluridine and Tipiracil Hydrochloride
Given PO
Allegheny General Hospital, Pittsburgh
MedStar Georgetown University Hospital, Washington D.C.
MedStar Washington Hospital Center, Washington D.C.
Duke University Medical Center, Durham
Emory University Hospital/Winship Cancer Institute, Atlanta
Aurora Cancer Care-Milwaukee West, Wauwatosa
Mayo Clinic in Rochester, Rochester
University of Chicago Comprehensive Cancer Center, Chicago
M D Anderson Cancer Center, Houston
Mayo Clinic in Arizona, Scottsdale
USC / Norris Comprehensive Cancer Center, Los Angeles
Cedars Sinai Medical Center, Los Angeles
UC San Diego Moores Cancer Center, La Jolla
Mayo Clinic in Florida, Jacksonville
Massachusetts General Hospital Cancer Center, Boston
Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Rutgers Cancer Institute of New Jersey, New Brunswick
National Cancer Institute (NCI)
NIH
Academic and Community Cancer Research United
OTHER